Trumenba

PreclinicalBiologic

Pfizer

Trumenba is one of 15 biologic programs targeting Gonorrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GonorrheaActive, not recruiting

GonorrheaPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Gonorrhea

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 2

Cipro

Garamycin

1 4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

4 7

Factive

LLG Chem

Approved

1 8

Azactam

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 9

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 3

1 10

Delafloxacin

MMelinta Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Vaccine

NCT07197762

Q4 2028

Phase 3Recruiting

Immunogenicity

NCT04166656

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Completed·UUCSF Benioff Children's Hospital Oakland·Phase 4·NCT02569632·18 enrolled

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04166656·84 enrolled

Gonorrhea1 trial

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed· Pfizer logo

Pfizer··NCT05873751·1,307,378 enrolled

Immunocompromised1 trial

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Completed· Pfizer logo

Pfizer·Phase 4·NCT04893811·53 enrolled

Vaccine1 trial

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

Recruiting·EEmory University·Phase 4·NCT07197762·125 enrolled

ART1 trial

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

Completed· Pfizer logo

Pfizer·Phase 3·NCT04440163·2,431 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Trumenba. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trumenba compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trumenba. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Trumenba

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Immunogenicity2 trials

Gonorrhea1 trial

Immunocompromised1 trial

Vaccine1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News